PLGA／TPGS-姜黄素纳米粒的制备及体外评价

以维生素E1000聚乙二醇琥珀酸酯（TPGS）为乳化剂,姜黄素为模型药物,聚乳酸-羟基乙酸为载体材料,采用O／W型乳化-溶剂挥发法制备聚乳酸-羟基乙酸-姜黄素纳米粒,以包封率和载药量为主要指标,单因素实验探索影响两指标的主要因素,正交试验设计优化制备工艺,结果表明,制备聚乳酸-羟基乙酸-姜黄素纳米粒的最佳工艺为：聚合物浓度4％,乳化剂TPGS浓度0．03％,超声时间8min,搅拌时间6h。以此工艺制备的载药纳米粒外形圆整光滑,粒度分布较为均匀,平均粒径为189．7nm,包封率为86．2％,载药量为7．45％。     

聚乳酸-羟基乙酸/改性纳米羟基磷灰石复合多孔支架材料的研制

聚乳酸-羟基乙酸(PLGA)/改性纳米羟基磷灰石(MHA)复合多孔组织工程支架材料的制备主要包含以下步骤:首先通过室温化学共沉淀法制备纳米羟基磷灰石,然后通过L-丙交酯在二甲苯溶液中聚合接枝纳米羟基磷灰石得到改性的纳米羟基磷灰石;最后通过改进的热致相分离两步初化法制备PLGA/MHA复合多孔支架.X射线衍射仪(XRD)显示纳米羟基磷灰石合成成功,透射电子显微镜(TEM)结果显示其为半径为30～50nm的球形,红外光谱显示聚乳酸成功的接枝到纳米羟基磷灰石表面;扫描电子显微镜(SEM)结果表明改进的热致相分离两步初化法制备的PLGA/MHA复合多孔支架的孔径在100～450μm.     

载卡托普利聚(乳酸-羟基乙酸)纳米纤维毡及其释药研究

应用静电纺丝技术,以Captopril(CPL)为模型药物,以聚(乳酸-羟基乙酸)(PLGA)为载体高分子材料制备CPL/PLGA载药纳米纤维。探讨了静电纺丝工艺参数,得出最佳较优纺丝条件为原液浓度20%(质量分数),载药量:m(CPL)∶m(PLGA)=2∶10,电压12.5kV,流速1mL/h,溶剂为V(二氯甲烷)∶V(丙酮)=2∶1。应用扫描电子显微镜(SEM)、傅立叶红外光谱仪(FT-IR)、差示扫描量热仪(DSC)和采用多晶衍射仪(XRD)对所制备的载药纤维进行了表征。体外(In vitro)释药性研究实验结果表明,PLGA载药纳米纤维具有明显的初期突释,随着缓冲溶液pH值增加,初期突释减弱,药物释放度也会随之减弱。     

羟基喜树碱叶酸-壳聚糖纳米粒的制备及其性能研究

为了提高羟基喜树碱对肿瘤组织的靶向性,增强其抗肿瘤活性,延长其在体内的作用时间,以壳聚糖为药物载体,叶酸为肿瘤靶向配体,三聚磷酸钠为聚阴离子,利用静电相互作用的原理,通过离子交联法合成载羟基喜树碱的叶酸-壳聚糖(FA-CTS/HCPT)纳米粒。利用动态光散射、透射电镜以及红外等技术对纳米粒的结构、平均粒径及粒径分布、形态特征、表面电位、稳定性、对药物的包封率及载药量、体外释放等特点进行了初步研究。结果表明,所制得的纳米粒平均粒径为150nm;粒子形态圆整,大小均匀;表面电位+50.1mV;放置数十天纳米粒粒径几乎无变化,纳米粒具有很好的粒度稳定性;对羟基喜树碱包封率最高为89.9%,载药量最高为19.8%;在人工体液pH值为7.4条件下具有很好的缓释作用,用Higuchi方程拟合其体外释放曲线,得Higuchi方程:Q=14.529t1/2+8.3589(R2=0.9247),说明HCPT在人工体液的释放量与时间的平方根成直线关系,符合水不溶性骨架的释药性能。     

磁性壳聚糖-5-氟尿嘧啶纳米粒的制备及体外释药性能

采用交联-聚合法在超声波的作用下,制备了磁性壳聚糖-5-氟尿嘧啶纳米粒(M CN-Fu)。透射电子显微镜(TEM)和红外光谱(IR)等分析结果表明,M CN-Fu粒子外形规整,分散性好,粒径主要在50 nm~60 nm之间。紫外-可见光谱分析结果表明,M CN-Fu的载药量为21.3%,在磷酸盐缓冲溶液(pH=7.2)中,30 h的累积释药率为67.6%,具有良好缓释性能,并具有良好磁响应性能。     

聚乳酸/杆菌肽静电纺丝纤维的体外释药研究

为探讨聚乳酸纤维结构形貌对杆菌肽药物的缓慢释放行为及作用机理,通过静电纺丝法制备了聚乳酸/杆菌肽单轴纤维、聚乳酸/杆菌肽串珠和(聚乳酸/杆菌肽)-聚乳酸同轴核-壳纤维等聚乳酸/杆菌肽药物缓释体系,并采用红外光谱法和差热分析法对其化学结构和热性能进行了表征.利用紫外分光光度计法研究了不同载药体系的体外药物释放行为,并探索了不同降解时期载药纤维的质量和形貌变化规律.研究表明:杆菌肽与聚乳酸主要为物理结合;聚乳酸单轴纤维和串珠对杆菌肽的扩散释放机理,属于纯Fick扩散;采用单轴和同轴静电纺丝技术可以获得两种不同释药特性的载药纤维.单轴纤维和串珠能够将药物快速释放,适合抗生素的治疗;同轴纤维中药物受控释放,更适合长期、小剂量的药物释放.     

基于凝固浴剪切法制备多孔实心聚(乳酸-羟基乙酸)共聚物载药微球

以聚(乳酸-羟基乙酸)为基质材料,采用一种新颖的流动凝固浴剪切法制备包载盐酸万古霉素的载药微球,并研究微球的形貌结构、粒径、包封率、载药率、体外释放性能及其影响因素。结果表明,所制备的载药微球平均粒径在15~29μm范围,微球呈现内部实心表面多孔的复合结构;微球的包封率及载药可分别在15%~75%和1.5%~9.3%范围内调控。微球制备过程中的工艺条件对微球结构形貌、包封率、载药率及释放性能有重要影响,通过调整微球的粒径,可有效减缓释药过程中的突释现象。     

甘草酸羧甲基壳聚糖纳米粒的制备及其性能研究

通过正交试验设计优化钙离子交联法制备羧甲基壳聚糖纳米粒工艺条件,以透射电镜观察,纳米粒外观形态圆整;以激光粒度分析仪测定,纳米粒平均粒径为(131.2±5.27)nm;以高效液相色谱法测定,纳米粒包封率为(51.2±0.41)%,载药量为(16.7±0.29)%。对模型药物甘草酸的体外释放性能考察结果表明,所制备的纳米粒具有较好的控制药物释放的作用。     

海藻酸钠纳米粒制备的研究进展

纳米粒药物载体能帮助药物靶向传输及可控释放,是生物医药领域的重要研究方向。海藻酸钠生物相容性好、易于修饰及加工形成微纳米颗粒,作为药物载体的应用研究日渐增多。综述了制备海藻酸钠纳米粒的4种方法,即离子交联法、乳化法、静电络合法和自组装法,并指出了4种方法的优缺点。     

炭纤维增强羟基磷灰石/聚乳酸复合生物材料的力学性能和体外降解性能

采用溶液共混法制备了炭纤维(CF)增强羟基磷灰石(HA)/聚乳酸(PLA)三元复合生物材料。研究了该复合材料的力学性能和体外降解性能。CF/HA/PLA复合材料具有优异的力学性能, 弯曲强度和弯曲模量均随着HA含量的增加先升高后降低, 存在一个峰值, 可分别达到430MPa和26GPa。在PBS模拟体液中降解3个月, 弯曲强度和弯曲模量分别下降到初始值的30%和36%。SEM照片显示, 降解是从复合材料的界面开始的, 降解3个月后, 界面结合处出现缝隙, 吸水率增加到5%, 质量损失只有1.6%。PBS模拟体液的pH值下降在0.1之内, 有利于骨折部位的愈合。实验结果表明, 该复合材料的机械性能满足骨折内固定材料技术指标的要求。      

Antibody Conjugated PLGA Nanoparticles for Targeted Delivery of Paclitaxel Palmitate: Efficacy and Biofate in a Lung Cancer Mouse Model

Aberrant signaling of the epidermal growth factor receptor (EGFR) is common to a variety of human cancers and is also found to be over‐expressed in most cases of non‐small cell lung cancer. For the development of a molecularly targeted therapy, cetuximab‐conjugated nanoparticles (immunonanoparticles, INPs) are designed and loaded with the lipophilic paclitaxel palmitate (pcpl) prodrug. Oleyl cysteineamide (OCA) is synthesized whereby its amphiphilic nature enables interfacial anchoring and thiol surface functionalization of PLGA NPs, facilitating bioconjugation to cetuximab by thioether bonds. It is demonstrated that the in vitro targeting efficiency and improved cellular internalization and cytotoxicity of this targeted delivery system in lung cancer cells over‐expressing EGFR. A quantitative measure of the high binding affinity of INPs to EGFR is demonstrated using surface plasmon resonance. In vivo tolerability and enhanced efficacy of cetuximab pcpl INPs in a metastatic lung cancer model are reported. Its therapeutic efficacy in A549‐luc‐C8 lung tumors is shown using non‐invasive bioluminescent imaging. Intravenous administration of cetuximab pcpl INPs to mice results in significantly higher inhibition of tumor growth and increased survival rates as compared to the non‐targeted drug solution, drug‐loaded nanoparticles or blank INPs. Pharmacokinetics and organ biodistribution of the prodrug and parent drug are evaluated by LC‐MS/MS in lung tumor bearing mice. No enhanced total accumulation of nanoparticles or INPs is found at the tumor tissue. However, persistent pcpl levels with sustained conversion and release of paclitaxel are observed for the encapsulated prodrug possibly suggesting the formation of a drug reservoir. The overall results indicate the potential of this promising targeted platform for the improved treatment of lung cancer and other EGFR positive tumors.     

Memantine‐Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma

Glaucoma is a multifactorial neurodegenerative disease associated with retinal ganglion cells (RGC) loss. Increasing reports of similarities in glaucoma and other neurodegenerative conditions have led to speculation that therapies for brain neurodegenerative disorders may also have potential as glaucoma therapies. Memantine is an N‐methyl‐d ‐aspartate (NMDA) antagonist approved for Alzheimer's disease treatment. Glutamate‐induced excitotoxicity is implicated in glaucoma and NMDA receptor antagonism is advocated as a potential strategy for RGC preservation. This study describes the development of a topical formulation of memantine‐loaded PLGA‐PEG nanoparticles (MEM‐NP) and investigates the efficacy of this formulation using a well‐established glaucoma model. MEM‐NPs <200 nm in diameter and incorporating 4 mg mL^?1 of memantine were prepared with 0.35 mg mL^?1 localized to the aqueous interior. In vitro assessment indicated sustained release from MEM‐NPs and ex vivo ocular permeation studies demonstrated enhanced delivery. MEM‐NPs were additionally found to be well tolerated in vitro (human retinoblastoma cells) and in vivo (Draize test). Finally, when applied topically in a rodent model of ocular hypertension for three weeks, MEM‐NP eye drops were found to significantly (p < 0.0001) reduce RGC loss. These results suggest that topical MEM‐NP is safe, well tolerated, and, most promisingly, neuroprotective in an experimental glaucoma model.     

琼脂糖醋酸酯纳米粒子的制备及药物缓释性

通过纳米沉淀法制备了一种粒径均一的琼脂糖醋酸酯纳米粒子,并对影响粒径的相关因素进行了研究。结果表明,纳米粒子分别随着二甲基亚砜(DMSO)与水的比率、姜黄素含量及琼脂糖醋酸酯(AA)的浓度的增加而增大,随转速的增加而下降,异丙醇和聚乙烯醇(PVA)浓度也有一定的影响。同时研究了载体对姜黄素的包载情况及缓释行为。结果显示,无异丙醇组中姜黄素载药率和包封率均比异丙醇组中的高。但两组都表明,随着姜黄素的含量增加,载药粒子的载药率不断增加,包封率不断降低。载药粒子大大延长了姜黄素的缓释时间。获得的琼脂糖醋酸酯纳米粒子可望用于姜黄素的控释。     

基于MEMS的微型药物控释系统释药特性研究

基于微纳米加工技术,设计一种可降解的植入式药物控释微载体,介绍利用紫外光刻（UV—LIGA）技术制备该类微载体的工艺。用聚羟基丙酸乙酸（PLGA）制作该微载体,分别对填充扑热息痛和扑尔敏两种药物的该类控释系统进行了实验研究,对比分析了在结构表面扎微孔和药物的溶解度对释药速率的影响情况,实验表明该类型微载体适用于植入式长期控释给药,而且累积给药量线性度较好。     

Sharpening the Thermal Release of DNA from Nanoparticles: Towards a Sequential Release Strategy

Unlike the sharp melting behavior of DNA‐linked nanoparticle aggregates, the melting of DNA strands from individual gold nanoparticles is broad despite the high surface density of bound DNA. Here, it is demonstrated how sharpened melting can be achieved in colloidal nanoparticle systems using branched DNA–doubler structures hybridized with complementary DNA‐doublers bound to the gold nanoparticle. Moreover, sharpened transitions are observed when DNA‐doublers are hybridized with linear DNA‐modified gold nanoparticles. This result suggests that the DNA density on nanoparticles is intrinsically great enough to form cooperative structures with the DNA‐doublers. Finally, by introducing abasic destabilizing groups, the melting temperature of these DNA‐doublers decreases without decreasing the sharpness. Consequently, by varying the temperature, two DNA‐doublers with different stabilities dissociate sequentially from the gold nanoparticle surface, without overlapping and within a narrow temperature window. Owing to the excellent thermal selectivities exhibited by this system, the implementation of DNA‐doublers in sequential photothermal therapies and with other nanomedicine delivery agents that rely on DNA dissociation as the mechanism of selective release is anticipated.     

Formulation development and in vitro evaluation of gentamicin sulfate-loaded PLGA nanoparticles based film for the treatment of surgical site infection by Box–Behnken design

Objective: Gentamicin sulfate (GS)–loaded poly lactic-co-glycolic acid (PLGA) polymeric nanoparticles (PNPs) were developed and incorporated in film for the treatment of surgical site infection (SSI).

Method: PNPs were prepared by double emulsification solvent removal technique using ethyl acetate solution containing PLGA and polyvinyl alcohol (PVA) as an emulsifier. The emulsion was re-emulsified using Gum Kondagogu (GKK). PNPs loaded film was prepared with 5% w/v solution of pullulan in PNPs using solvent casting technique. Design of Experiment (DoE) study using Box–Behnken design was performed for the optimization of PNPs. Drug release study was carried out for PNPs at phosphate buffer saline (PBS) pH 6.4 and simulated wound fluid (SWF) pH 7.4.

Result: PNPs were found to have average particle size 280?±?12.04?nm, polydispersity index (PDI) 0.15?±?0.01 and zeta potential – 4.9?±?0.84?mV. Scanning electron microscopy (SEM) showed spherical nature of PNPs along with particle size of 160?±?35.30?nm confirmed with transmission electron microscopy (TEM). PNPs were found to be effective against Pseudomonas aeruginosa (PA) and Staphylococcus aureus (SA). Optimized batch of film showed in vitro disintegration time below 8?min with tensile strength (TS) 0.06?±?0.03 N/cm² and percentage elongation (% E) 70.95?±?4.29. X-ray diffraction study (XRD) confirmed amorphous nature of GS, PLGA, pullulan, GKK and film.

Conclusion: PNPs showed controlled release of GS after an initial burst release. Developed film can be an effective approach for management of SSI and control of antibiotic induced drug resistance.     

Synthesis and Assembly of Click‐Nucleic‐Acid‐Containing PEG–PLGA Nanoparticles for DNA Delivery

Co‐delivery of both chemotherapy drugs and siRNA from a single delivery vehicle can have a significant impact on cancer therapy due to the potential for overcoming issues such as drug resistance. However, the inherent chemical differences between charged nucleic acids and hydrophobic drugs have hindered entrapment of both components within a single carrier. While poly(ethylene glycol)‐block‐poly(lactic‐co‐glycolic acid) (PEG–PLGA) copolymers have been used successfully for targeted delivery of chemotherapy drugs, loading of DNA or RNA has been poor. It is demonstrated that significant amounts of DNA can be encapsulated within PLGA‐containing nanoparticles through the use of a new synthetic DNA analog, click nucleic acids (CNAs). First, triblock copolymers of PEG‐CNA‐PLGA are synthesized and then formulated into polymer nanoparticles from oil‐in‐water emulsions. The CNA‐containing particles show high encapsulation of DNA complementary to the CNA sequence, whereas PEG‐PLGA alone shows minimal DNA loading, and non‐complementary DNA strands do not get encapsulated within the PEG‐CNA‐PLGA nanoparticles. Furthermore, the dye pyrene can be successfully co‐loaded with DNA and lastly, a complex, larger DNA sequence that contains an overhang complementary to the CNA can also be encapsulated, demonstrating the potential utility of the CNA‐containing particles as carriers for chemotherapy agents and gene silencers.